Perspective Therapeutics (CATX) Stock Forecast, Price Target & Predictions


OverviewOwnershipChart

CATX Stock Forecast


Perspective Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 165.49% upside from CATX’s last price of $6.78) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

CATX Price Target


The average price target for Perspective Therapeutics (CATX) is $18.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $3.00. This represents a potential 165.49% upside from CATX's last price of $6.78.

CATX Analyst Ratings


Buy

According to 6 Wall Street analysts, Perspective Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CATX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Perspective Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024David DaiUBS$20.00$11.6971.09%194.99%
Oct 14, 2024Jeff JonesOppenheimer$22.00$12.6673.78%224.48%
Sep 25, 2024Nicole GerminoTruist Financial$21.00$12.2871.01%209.73%
Jul 25, 2024Alec StranahanBank of America Securities$24.00$12.8287.21%253.98%
Jun 18, 2024Jeff JonesOppenheimer$19.00$11.9359.26%180.24%
Jun 14, 2024Gregory RenzaRBC Capital$3.00$1.15161.21%-55.75%
May 15, 2024Jeff JonesOppenheimer$2.00$1.5727.39%-70.50%
Row per page
Go to

The latest Perspective Therapeutics stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $20.00, which represents a 71.09% increase from the stock price at the time of the forecast ($11.69), and a 194.99% increase from CATX last price ($6.78).

Perspective Therapeutics Price Target by Period


1M3M12M
# Anlaysts137
Avg Price Target$20.00$21.00$15.86
Last Closing Price$6.78$6.78$6.78
Upside/Downside194.99%209.73%133.92%

In the current month, the average price target of Perspective Therapeutics stock is $20.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 194.99% increase as opposed to Perspective Therapeutics's last price of $6.78. This month's average price target is down -4.76% compared to last quarter, and up 26.10% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024UBS-BuyInitialise
Oct 14, 2024OppenheimerOutperformOutperformHold
Sep 30, 2024Wedbush-OutperformInitialise
Jun 18, 2024OppenheimerOutperformOutperformHold
Jun 14, 2024RBC CapitalOutperformOutperformHold
May 15, 2024OppenheimerOutperformOutperformHold
May 14, 2024RBC Capital-OutperformInitialise
May 09, 2024Cantor Fitzgerald-OverweightInitialise
Apr 09, 2024B. RileyBuyBuyHold
Apr 01, 2024OppenheimerOutperformOutperformHold
Row per page
Go to

Perspective Therapeutics's last stock rating was published by UBS on Oct 24, 2024. The company Initialise its CATX rating from "null" to "Buy".

Perspective Therapeutics Financial Forecast


Perspective Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
Revenue--------------$1.50M$1.83M$1.83M$1.72M$2.50M$2.91M$2.82M$2.56M$2.71M$2.60M$2.36M$2.38M$2.28M$2.88M$2.21M
Avg Forecast$2.06M$2.05M$2.03M$2.02M$100.80K$99.80K$98.81K$147.83K$308.62K$292.76K$183.48K$368.80K$1.85M$2.60M$2.06M$2.84M$2.84M$2.95M$2.49M$2.70M$2.43M$2.40M$2.85M$2.70M$2.54M$2.30M$2.12M$1.93M$1.93M
High Forecast$3.03M$3.01M$2.99M$2.98M$148.23K$146.76K$145.31K$149.58K$453.86K$430.53K$183.72K$368.90K$2.23M$3.82M$3.03M$4.18M$2.98M$2.95M$2.49M$2.70M$2.43M$2.40M$2.85M$2.70M$2.54M$2.30M$2.12M$1.93M$1.97M
Low Forecast$1.06M$1.05M$1.05M$1.04M$51.88K$51.37K$50.86K$146.08K$158.85K$150.69K$183.24K$368.70K$1.47M$1.34M$1.06M$1.46M$2.71M$2.95M$2.49M$2.70M$2.43M$2.40M$2.85M$2.70M$2.54M$2.30M$2.12M$1.93M$1.89M
# Analysts22221114631111111111111111111
Surprise %--------------0.73%0.64%0.65%0.58%1.01%1.08%1.16%1.07%0.95%0.96%0.93%1.04%1.08%1.49%1.14%

Perspective Therapeutics's average Quarter revenue forecast for Sep 23 based on 1 analysts is $2.60M, with a low forecast of $1.34M, and a high forecast of $3.82M. CATX's average Quarter revenue forecast represents a 73.33% increase compared to the company's last Quarter revenue of $1.50M (Jun 23).

Perspective Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114631111111111111111111
EBITDA--------------$-11.08M$-10.65M$-3.10M$-4.21M$-2.11M$-1.38M$-1.64M$-2.21M$-1.09M$-762.00K$-859.00K$-714.00K$-1.19M$-512.00K$-864.00K
Avg Forecast$-1.28M$-1.27M$-1.27M$-1.26M$-62.69K$-62.07K$-61.45K$-91.94K$-191.94K$-182.08K$-114.11K$-229.37K$-1.15M$-1.62M$-1.28M$-1.77M$-1.77M$-1.83M$-1.55M$-1.68M$-1.51M$-1.49M$-1.77M$-1.68M$-1.58M$-1.43M$-1.32M$-1.20M$-1.20M
High Forecast$-658.97K$-655.15K$-651.37K$-647.60K$-32.27K$-31.95K$-31.63K$-90.85K$-98.79K$-93.72K$-113.96K$-229.31K$-911.78K$-832.29K$-659.43K$-910.40K$-1.69M$-1.83M$-1.55M$-1.68M$-1.51M$-1.49M$-1.77M$-1.68M$-1.58M$-1.43M$-1.32M$-1.20M$-1.18M
Low Forecast$-1.88M$-1.87M$-1.86M$-1.85M$-92.19K$-91.27K$-90.37K$-93.03K$-282.27K$-267.76K$-114.26K$-229.43K$-1.39M$-2.38M$-1.88M$-2.60M$-1.85M$-1.83M$-1.55M$-1.68M$-1.51M$-1.49M$-1.77M$-1.68M$-1.58M$-1.43M$-1.32M$-1.20M$-1.22M
Surprise %--------------8.65%6.02%1.76%2.29%1.36%0.82%1.08%1.49%0.62%0.45%0.54%0.50%0.90%0.43%0.72%

undefined analysts predict CATX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Perspective Therapeutics's previous annual EBITDA (undefined) of $NaN.

Perspective Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114631111111111111111111
Net Income--------------$-11.11M$-371.00K$-2.20M$-3.93M$-2.01M$-1.21M$-1.60M$-2.24M$-1.06M$-745.00K$-868.00K$-713.00K$-1.19M$-545.00K$-897.00K
Avg Forecast$-89.78M$-86.97M$-84.17M$-84.17M$-107.67M$-101.05M$-93.93M$-86.29M$-71.54M$-59.86M$-57.71M$-78.56M$-126.25M$-84.17M$334.51M$-28.06M$-21.04M$-21.04M$-28.06M$-28.06M$-28.06M$-28.06M$-28.06M$-37.41M$-37.41M$-37.41M$-46.76M$-56.11M$-5.61M
High Forecast$-33.14M$-32.10M$-31.07M$-31.07M$-39.74M$-37.30M$-34.67M$-70.11M$-54.37M$-22.10M$-21.30M$-29.00M$-46.60M$-31.07M$539.15M$-10.36M$-7.77M$-21.04M$-28.06M$-28.06M$-28.06M$-28.06M$-28.06M$-37.41M$-37.41M$-37.41M$-46.76M$-56.11M$-5.61M
Low Forecast$-144.70M$-140.18M$-135.66M$-135.66M$-173.54M$-162.87M$-151.39M$-99.77M$-82.98M$-96.48M$-93.02M$-126.61M$-203.49M$-135.66M$123.47M$-45.22M$-33.91M$-21.04M$-28.06M$-28.06M$-28.06M$-28.06M$-28.06M$-37.41M$-37.41M$-37.41M$-46.76M$-56.11M$-5.61M
Surprise %---------------0.03%0.01%0.10%0.19%0.07%0.04%0.06%0.08%0.04%0.02%0.02%0.02%0.03%0.01%0.16%

Perspective Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CATX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Perspective Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114631111111111111111111
SG&A--------------$5.98M$7.83M$2.99M$3.91M$2.24M$2.27M$2.32M$2.60M$1.97M$1.76M$1.75M$1.65M$1.94M$1.96M$1.74M
Avg Forecast$2.18M$2.17M$2.16M$2.14M$106.83K$105.78K$104.73K$156.69K$327.12K$310.31K$194.47K$390.90K$1.96M$2.76M$2.18M$3.01M$3.01M$3.13M$2.63M$2.86M$2.57M$2.54M$3.02M$2.86M$2.69M$2.44M$2.24M$2.05M$2.05M
High Forecast$3.21M$3.19M$3.17M$3.15M$157.11K$155.55K$154.01K$158.54K$481.05K$456.33K$194.73K$391.00K$2.37M$4.05M$3.21M$4.43M$3.16M$3.13M$2.63M$2.86M$2.57M$2.54M$3.02M$2.86M$2.69M$2.44M$2.24M$2.05M$2.09M
Low Forecast$1.12M$1.12M$1.11M$1.10M$54.99K$54.44K$53.90K$154.83K$168.37K$159.72K$194.22K$390.79K$1.55M$1.42M$1.12M$1.55M$2.87M$3.13M$2.63M$2.86M$2.57M$2.54M$3.02M$2.86M$2.69M$2.44M$2.24M$2.05M$2.01M
Surprise %--------------2.74%2.60%0.99%1.25%0.85%0.79%0.90%1.02%0.65%0.62%0.65%0.68%0.86%0.96%0.85%

Perspective Therapeutics's average Quarter SG&A projection for Sep 23 is $2.76M, based on 1 Wall Street analysts, with a range of $1.42M to $4.05M. The forecast indicates a -53.95% fall compared to CATX last annual SG&A of $5.98M (Jun 23).

Perspective Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114631111111111111111111
EPS--------------$-0.04$-0.00$-0.02$-0.03$-0.01$-0.01$-0.01$-0.02$-0.01$-0.01$-0.01$-0.01$-0.02$-0.01$-0.01
Avg Forecast$-0.32$-0.31$-0.30$-0.30$-0.38$-0.36$-0.33$-0.31$-0.25$-0.21$-0.21$-0.28$-0.45$-0.30$1.19$-0.10$-0.07$-0.07$-0.10$-0.10$-0.10$-0.10$-0.10$-0.13$-0.13$-0.13$-0.17$-0.20$-0.02
High Forecast$-0.12$-0.11$-0.11$-0.11$-0.14$-0.13$-0.12$-0.25$-0.19$-0.08$-0.08$-0.10$-0.17$-0.11$1.92$-0.04$-0.03$-0.07$-0.10$-0.10$-0.10$-0.10$-0.10$-0.13$-0.13$-0.13$-0.17$-0.20$-0.02
Low Forecast$-0.52$-0.50$-0.48$-0.48$-0.62$-0.58$-0.54$-0.36$-0.30$-0.34$-0.33$-0.45$-0.73$-0.48$0.44$-0.16$-0.12$-0.07$-0.10$-0.10$-0.10$-0.10$-0.10$-0.13$-0.13$-0.13$-0.17$-0.20$-0.02
Surprise %---------------0.03%0.02%0.21%0.37%0.14%0.09%0.11%0.16%0.07%0.05%0.08%0.08%0.10%0.04%0.66%

According to undefined Wall Street analysts, Perspective Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CATX previous annual EPS of $NaN (undefined).

Perspective Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CATXPerspective Therapeutics$6.78$18.00165.49%Buy
SGHTSight Sciences$3.77$9.00138.73%Hold
LUNGPulmonx$6.00$11.9398.83%Buy
HYPRHyperfine$0.87$1.6083.91%Buy
KIDSOrthoPediatrics$24.32$39.6062.83%Buy
SIBNSI-BONE$12.32$20.0062.34%Buy
NPCENeuroPace$9.18$12.8840.31%Buy
LIVNLivaNova$51.36$70.5037.27%Buy
OFIXOrthofix Medical$18.73$24.0028.14%-
CVRXCVRx$13.42$16.3321.68%Buy
FNAParagon 28$10.50$11.509.52%Buy
SRDXSurmodics$39.19$39.500.79%Buy

CATX Forecast FAQ


Is Perspective Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Perspective Therapeutics (CATX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CATX's total ratings.

What is CATX's price target?

Perspective Therapeutics (CATX) average price target is $18 with a range of $3 to $24, implying a 165.49% from its last price of $6.78. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Perspective Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CATX stock, the company can go up by 165.49% (from the last price of $6.78 to the average price target of $18), up by 253.98% based on the highest stock price target, and down by -55.75% based on the lowest stock price target.

Can Perspective Therapeutics stock reach $10?

CATX's average twelve months analyst stock price target of $18 supports the claim that Perspective Therapeutics can reach $10 in the near future.

What is Perspective Therapeutics's current price target trend?

1 Wall Street analyst forecast a $20 price target for Perspective Therapeutics (CATX) this month, up 194.99% from its last price of $6.78. Compared to the last 3 and 12 months, the average price target increased by 209.73% and increased by 133.92%, respectively.

What are Perspective Therapeutics's analysts' financial forecasts?

Perspective Therapeutics's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $848.02K (high $1.18M, low $506.47K), average EBITDA is $-527K (high $-315K, low $-733K), average net income is $-312M (high $-181M, low $-431M), average SG&A $898.84K (high $1.25M, low $536.82K), and average EPS is $-1.111 (high $-0.646, low $-1.535). CATX's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $4.26M (high $6.26M, low $2.19M), average EBITDA is $-2.648M (high $-1.363M, low $-3.895M), average net income is $-377M (high $-139M, low $-608M), average SG&A $4.51M (high $6.64M, low $2.32M), and average EPS is $-1.344 (high $-0.496, low $-2.166).

Did the CATX's actual financial results beat the analysts' financial forecasts?

Based on Perspective Therapeutics's last annual report (Jun 2022), the company's revenue was $10.8M, beating the average analysts forecast of $10.01M by 7.87%. Apple's EBITDA was $-7.391M, beating the average prediction of $-6.224M by 18.75%. The company's net income was $-7.153M, missing the average estimation of $-112M by -93.63%. Apple's SG&A was $9.42M, missing the average forecast of $10.61M by -11.15%. Lastly, the company's EPS was $-0.0504, missing the average prediction of $-0.4 by -87.40%. In terms of the last quarterly report (Jun 2023), Perspective Therapeutics's revenue was $1.5M, missing the average analysts' forecast of $2.06M by -27.18%. The company's EBITDA was $-11.078M, beating the average prediction of $-1.281M by 764.67%. Perspective Therapeutics's net income was $-11.106M, missing the average estimation of $334.51M by -103.32%. The company's SG&A was $5.98M, beating the average forecast of $2.18M by 174.06%. Lastly, the company's EPS was $-0.0397, missing the average prediction of $1.19 by -103.33%